Stoke Therapeutics (STOK) Projected to Post Earnings on Tuesday

Stoke Therapeutics (NASDAQ:STOK) is expected to be posting its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Stoke Therapeutics to post earnings of ($0.75) per share and revenue of $5.32 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 26, 2026 at 5:00 PM ET.

Stoke Therapeutics Stock Down 9.0%

Shares of NASDAQ:STOK opened at $33.19 on Monday. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $40.22. The stock’s 50 day moving average is $32.71 and its 200-day moving average is $29.70. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a research note on Monday, January 5th. Canaccord Genuity Group raised their price objective on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, January 5th. UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a report on Monday, December 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright raised their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.25.

Insiders Place Their Bets

In other news, insider Arthur Tzianabos sold 4,355 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $40.00, for a total value of $174,200.00. Following the completion of the sale, the insider owned 31,339 shares in the company, valued at $1,253,560. This represents a 12.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Adrian R. Krainer sold 33,243 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the completion of the sale, the director owned 283,302 shares of the company’s stock, valued at approximately $11,258,421.48. This represents a 10.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its position in Stoke Therapeutics by 1.2% in the 4th quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock worth $935,000 after purchasing an additional 354 shares in the last quarter. Kestra Advisory Services LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Stoke Therapeutics by 5.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after buying an additional 1,149 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Stoke Therapeutics by 12.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock worth $296,000 after buying an additional 1,313 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Stoke Therapeutics by 2.2% in the fourth quarter. Swiss National Bank now owns 75,700 shares of the company’s stock valued at $2,403,000 after acquiring an additional 1,600 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.